That's why I said the Insto might be interested if they see commercialisation in Europe and excellent evaluation from the clinic (the ED evaluation in the UK and Germany will be delay for another year given COVID-19 you would think), there is no arguing ResAppDx has massive potential and they would know this as well.
Ann: ResApp appoints VP, Commercial to progress growth strategy, page-45
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 187 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)